Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/56384
Tipo
ArtículoDerechos de autor
Acceso restringido
Colecciones
- INI - Artigos de Periódicos [3397]
Metadatos
Mostrar el registro completo del ítem
BARRIERS TO UPTAKE OF LONG-ACTING ANTIRETROVIRAL PRODUCTS FOR TREATMENT AND PREVENTION OF HIV IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS)
Low- and Middle-Income Countries
Long-acting injectable antiretroviral therapy
Patient Reported Outcomes
Afiliación
Joint Clinical Research Centre. Kampala, Uganda.
Universidad de Chile. Faculty of Medicine. Santiago, Chile.
Institute of HIV Research and Innovation in Bangkok. Bangkok, Thailand.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of the Witwatersrand. Faculty of Health Sciences. Wits Reproductive Health and HIV Institute. Johannesburg, South Africa.
Universidad de Chile. Faculty of Medicine. Santiago, Chile.
Institute of HIV Research and Innovation in Bangkok. Bangkok, Thailand.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of the Witwatersrand. Faculty of Health Sciences. Wits Reproductive Health and HIV Institute. Johannesburg, South Africa.
Resumen en ingles
Long-acting injectable antiretroviral therapy (LA ART) has been found to be non-inferior to daily oral ART in phase 3 clinical trials and is poised to soon enter routine clinical care. This treatment modality has the potential to address many barriers to daily oral ART adherence among people living with human immunodeficiency virus (HIV) and for HIV Pre-Exposure prevention. Data from the Patient Reported Outcomes (PROs) showed high rates of satisfaction, acceptability, tolerability and preference for the LA regimen, compared with the daily oral treatment. Once LA ART is available, access and uptake will be limited because of current knowledge gaps in the use of these agents and multiple challenges many specific to low-income and middle-income countries, where the epidemic is most concentrated and HIV prevention and treatment options are limited. These gaps will lead to multiple systems-level and individual-level barriers to implementation. Anticipating and addressing these gaps and barriers will help fulfill the promise of these agents against the pandemic.
Palabras clave en ingles
HIVLow- and Middle-Income Countries
Long-acting injectable antiretroviral therapy
Patient Reported Outcomes
Compartir